On Nov 27, major Wall Street analysts update their ratings for $Alector (ALEC.US)$, with price targets ranging from $3 to $7.
Morgan Stanley analyst Jeffrey Hung downgrades to a sell rating, and adjusts the target price from $10 to $3.
TD Cowen analyst Yaron Werber maintains with a buy rating.
Mizuho Securities analyst Graig Suvannavejh maintains with a buy rating.
H.C. Wainwright analyst Andrew Fein maintains with a buy rating, and adjusts the target price from $35 to $7.
Furthermore, according to the comprehensive report, the opinions of $Alector (ALEC.US)$'s main analysts recently are as follows:
Following the Phase 2 INVOKE-2 study results indicating that AL002 did not decelerate Alzheimer's progression nor affect disease biomarkers, there's a tempered perspective on this drug's immediate potential. Nonetheless, optimism remains for the potential of latozinemab, though the focus may shift more favorably towards other opportunities within the analyst's coverage, pending further data expected from the Phase 3 INFRONT-3 trials in frontotemporal dementia projected around late 2025 or early 2026.
The activation of TREM2 showed limited efficacy in Alzheimer's disease, representing a challenge for the domain of genome-wide association studies-driven medicine. Additionally, the mechanism of ARIA-E may need further evaluation.
Here are the latest investment ratings and price targets for $Alector (ALEC.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间11月27日，多家华尔街大行更新了$Alector (ALEC.US)$的评级，目标价介于3美元至7美元。
摩根士丹利分析师Jeffrey Hung下调至卖出评级，并将目标价从10美元下调至3美元。
TD Cowen分析师Yaron Werber维持买入评级。
瑞穗证券分析师Graig Suvannavejh维持买入评级。
H.C. Wainwright分析师Andrew Fein维持买入评级，并将目标价从35美元下调至7美元。
此外，综合报道，$Alector (ALEC.US)$近期主要分析师观点如下：
根据第2阶段INVOKE-2研究结果表明，AL002未能减缓阿尔茨海默病的进展，也没有影响疾病生物标志物，对该药物的即时潜力持谨慎态度。尽管如此，对latozinemab的潜力仍然持乐观态度，尽管焦点可能更有利于分析师所涵盖的其他机会，在2025年底或2026年初预计从Frontotemporal痴呆第3阶段INFRONt-3试验中预期获得更多数据。
TREM2的激活在阿尔茨海默病中显示出有限的疗效，这代表了基因组范围关联研究驱动医学领域的挑战。此外，ARIA-E的机制可能需要进一步评估。
以下为今日4位分析师对$Alector (ALEC.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
